The link between cholesterol and Alzheimer's disease
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
A leading hypothesis on the pathophysiology of Alzheimer's disease (AD) is the mis-metabolism of amyloid precursor protein. This mis-metabolism causes the 42-amino acid form of A beta(Abeta42) to form oligomers that in turn start a chain of events leading to the accumulation of amyloid plaques. Vascular factors such as hypertension, hypercholesterolemia and diabetes as well as the inheritance of the epsilon4 allele of the ApoE gene are risk factors for AD. These risks are thought to promote the production of beta-amyloid (Abeta). An association between cholesterol and the development of AD was suggested in 1994 and since then, research has confirmed a link between cholesterol and the development of AD. A high cholesterol level in mid-life is a risk for AD and statins i.e. cholesterol-lowering drugs, reduce this risk. Statins inhibit enzymes involved in the endogenous synthesis of cholesterol and evidence is mounting that they also affect enzymes in Abeta metabolism i.e. beta-secretase. This normalises the breakdown of the precursor of Abeta, amyloid precursor protein, thereby promoting the nonamyloidogenic pathway. This review focusses on the link between cholesterol and Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 2×
“…approximately 200 kDa (Yu et al. 1998; Li et al. 2000) and contains several proteins of which the most abundant are g-secretase, nicastrin, PEN-2 and APH-1 (Prokop et al. 2004). g-Secretase exists in two forms called presenilin-1 and presenilin-2 (Levy-Lahad et al. 1995; Sherring- ton et al. 1995).”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 2×
“According to the leading hypothesis on the pathophysiology of AD (Hardy and Allsop 1991; Selkoe 2000), mismetabolism of APP causes increased production of Ab42 which causes intraneuronal oligomerisation of Ab42 (Walsh et al.”
BackgroundA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 2×
“1997), and antioxidants (Sano et al. 1997), may also give protection against AD.”
BackgroundDeficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 1×
“Presenilin-1 seems to be the dominant g-secretase in generating Ab (De Strooper et al. 1998).”
Background15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726 · cited 3×
“For instance, blood pressure and cholesterol levels may return to normal, as has been shown in some studies (Skoog et al. 1996b; Notkola et al. 1998).”
BackgroundResultKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 2×
“However, the formation of amyloid plaques and the development of dementia have also been associated with non-genetic factors such as hypertension (Skoog 1997), hypercholesterolaemia (Kivipelto et al. 2001) and diabetes (Ott et al.”
BackgroundFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 2×
“Animal models have been used to establish the relation between Ab and NFTs. Stereotactic injection of Ab42 into the somatosensory cortex and hippocampus of P301L transgenic (human tau- mutation) and wild-type mice induced a five-fold increase in NFT formation in P301L mice only (Gotz et al. 2001).”
BackgroundMethodRapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522 · cited 1×
“Also at physiological concentrations, zinc rapidly precipitates soluble Ab40 into protease-resistant amyloid-like aggregates in vitro (Bush et al. 1994a,b).”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“One study has shown that by using peripheral anti-Ab antibodies (which do not cross the blood /brain barrier), it is possible to reduce not only free plasma levels of Ab but also the brain load of plaques in the transgenic APP mice (DeMattos et al. 2001).”
BackgroundGoedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., & Klug, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4051 · Cited by 1,134 · cited 2×
“Both PHFs and straight filaments are composed predominantly of abnormally hyperpho- sphorylated tau proteins (Goedert et al. 1988; Wischik et al. 1988).”
Background
Cited by
Taylor, A. A., Tsuji, J. S., Garry, M. R., McArdle, M. E., Goodfellow, W. L., Adams, W. J., & Menzie, C. A. (2020) · Environmental Management · doi:10.1007/s00267-019-01234-y · Cited by 512
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Roher, A. E., Esh, C. L., Kokjohn, T. A., Castaño, E. M., Van Vickle, G. D., Kalback, W. M., Patton, R. L., Luehrs, D. C., Daugs, I. D., Kuo, Y., et al. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.10.004 · Cited by 414
Role of NAD+ in regulating cellular and metabolic signaling pathways
Amjad, S., Nisar, S., Bhat, A. A., Shah, A. R., Frenneaux, M. P., Fakhro, K., Haris, M., Reddy, R., Patay, Z., Baur, J., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101195 · Cited by 384
Statins and the Brain: More than Lipid Lowering Agents?
Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170703101816 · Cited by 116
Meng, Y., Baldwin, C. T., Bowirrat, A., Waraska, K., Inzelberg, R., Friedland, R. P., & Farrer, L. A. (2006) · The American Journal of Human Genetics · doi:10.1086/503687 · Cited by 72
Metadata
- Authors
- Sjögren, M., & Blennow, K.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2005-05
- Volume
- 6
- Issue
- 2
- Pages
- 85-97
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2157885834
- Cited by
- 56
- References
- 28
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The link between cholesterol and Alzheimer's disease. https://app.cochat.ai/papers/10.1080/15622970510029795
- The paper
- Sjögren, M., & Blennow, K. (2005). The link between cholesterol and Alzheimer's disease. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622970510029795
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.